Results 21 to 30 of about 108,835 (233)

Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. [PDF]

, 1990
BALB/c mice infected with Leishmania major develop fatal, progressive disease, despite an immune response characterized by expansion of CD4+ T cells in the draining lymph nodes.
Dawkins, RS, Heinzel, FP, Holaday, BJ, Locksley, RM, Pu, RT, Sadick, MD   +5 more
core   +1 more source

The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination [PDF]

, 2012
Background: Neglected tropical diseases (NTDs) are a group of chronic parasitic diseases and related conditions that are the most common diseases among the 2·7 billion people globally living on less than US$2 per day.
A Alemu, A Aseffa, A Deressa, A Haileamlak, A Yami, Abraham Aseffa, AD Bryceson, Ahmed Ali, AM Dorkenoo, Asrat Hailu, AZ Zein, B Erko, B Erko, B Liese, B Yakob, BA Boatin, C Bogh, C Hanson, C Prasittisuk, C Sikorski, Central Statistical Agency [Ethiopia], ICF International, D Fekadu, DG Addiss, DH Molyneux, DH Molyneux, DR ten Eyck, E Litt, E Negera, E Negera, E Ruiz-Tiben, E Yimer, EW Price, F Demissie, F Tekola, FMOH, FMOH, FMoH, G Davey, G Davey, G Davey, G Mengistu, G Tefera, Gail Davey, GS Smith, H Birrie, H Kloos, H Kloos, J Alvar, J Alvar, JH Kolaczinski, JH Kolaczinski, JO Gyapong, K Bogel, KA Grépin, Kadu Meribo, Kebede Deribe, L Erosie, L Jemaneh, M Fekadu, M Fekadu, M Herrero, MA Brady, MC Baker, Ministry of Health, MJ Burton, MJ Taylor, N Kebede, NB Kabatereine, P Steinmann, PJ Hotez, PJ Hotez, PJ Hotez, PJ Hotez, PJ Hotez, PM Emerson, R ter Horst, RL Pullan, RW Ashford, S Bashaye, S Brooker, S Brooker, S Cairncross, S Negash, SG Gundersen, T Wondimagegnehu, Teshome Gebre, The Carter Center, W Shiferaw, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO, Y Berhane, Z Tadesse, ZA Zein   +103 more
core   +2 more sources

Life Cycle Stage-Specific Accessibility of Leishmania donovani Chromatin at Transcription Start Regions

mSystems, 2021
Leishmaniacistrans
Janne Grünebast, Stephan Lorenzen, Julia Zummack, Joachim Clos   +3 more
doaj   +3 more sources

Treatment-Based Strategy for the Management of Post-Kala-Azar Dermal Leishmaniasis Patients in the Sudan

Journal of Tropical Medicine, 2013
Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that affects more than 50% of successfully treated visceral leishmaniasis (VL) patients in Sudan.
A. M. Musa, E. A. G. Khalil, B. M. Younis, M. E. E. Elfaki, M. Y. Elamin, A. O. A. Adam, H. A. A. Mohamed, M. M. M. Dafalla, A. A. Abuzaid, A. M. El-Hassan   +9 more
doaj   +1 more source

Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection [PDF]

, 2014
Background/Purpose: A proper adjuvant has a relevant role in vaccine formulations to generate an effective immune response. In this study, total Leishmania antigen (TLA) formulated with Montanide ISA 763 or R848 as adjuvants were evaluated as a first ...
Cargnelutti, Diego Esteban, Celedon, Verónica, Cuello Carrión, Fernando Darío, Garcia Bustos, Maria Fernanda, Morea, Gastón, Salomón, María Cristina, Scodeller, Eduardo   +6 more
core   +1 more source

Poor adherence is a major barrier to the proper treatment of cutaneous leishmaniasis: A case-control field assessment in Iran

International Journal for Parasitology: Drugs and Drug Resistance, 2023
Leishmaniasis is an overlooked, poverty-stricken, and complex disease with growing social and public health problems. In general, leishmaniasis is a curable disease; however, there is an expansion of unresponsive cases to treatment in cutaneous ...
Mehdi Bamorovat, Iraj Sharifi, Setareh Agha Kuchak Afshari, Ali Karamoozian, Amirhossein Tahmouresi, Amireh Heshmatkhah, Ehsan Salarkia, Ahmad Khosravi, Maryam Hakimi Parizi, Maryam Barghi   +9 more
doaj   +1 more source

Laryngeal Leishmaniasis [PDF]

International Archives of Otorhinolaryngology, 2012
Introduction: Leishmaniasis is classified into three clinical presentations: visceral, coetaneous and mucocutaneous. The latter is usually secondary to hematogenous spread after months or years of skin infection and can manifest as infiltrative lesions, ulcerated or vegetating in nose, pharynx, larynx and mouth, associated or not with ...
Moraes, Bruno Teixeira de, Amorim Filho, Francisco de Souza, Caporrino Neto, José, Saraceni Neto, Paulo, Melo Júnior, José Elson Santiago de   +4 more
openaire   +4 more sources

Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment

Annals of Saudi Medicine, 2014
BACKGROUND AND OBJECTIVES: Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In Sudan, VL is caused by L donovani. Most drugs used to treat VL, especially pentavalent antimony compounds (sodium stibogluconate, SSG),
Abubakr O. A. Adam, Mohamed M. M. Dafalla, Hatim A. A. Mohammed, Mohamed Y. Elamin, Brima M. Younis, Mona E. E. Elfaki, Ahmed M. Musa, Ahmed M. Elhassan, Eltahir A. G. Khalil   +8 more
doaj   +1 more source

Leishmaniasis [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
SummaryLeishmaniasis is a clinically heterogeneous group of diseases, caused by infection with protozoa of the genus Leishmania. The aggressiveness of the individual species, their organ preference and the host immune status determine disease course.
openaire   +2 more sources

The epidemiology of canine leishmaniasis: transmission rates estimated from a cohort study in Amazonian Brazil [PDF]

, 1997
We estimate the incidence rate, serological conversion rate and basic case reproduction number (R0) of Leishmania infantum from a cohort study of 126 domestic dogs exposed to natural infection rates over 2 years on Marajó Island, Pará State, Brazil.
Courtenay, O., Dye, C., Garcez, L.M., Quinnell, R.J.   +3 more
core   +1 more source